We are excited to announce that we have launched the generic version of Precedex® (Dexmedetomidine Hydrochloride Injection) in partnership with Sagent Pharmaceuticals. The product is available in 200 mcg per 50 mL and 400 mcg per 100 mL glass bottles.

This launch addresses the ongoing shortage of Dexmedetomidine Hydrochloride Injection in the U.S., providing a crucial option for sedation in intubated and mechanically ventilated patients in intensive care. Notably, this product received FDA First Cycle Approval, marking it as our second product to achieve this milestone.

Generics play a vital role in making high-quality medicines more accessible and affordable, which is at the heart of our mission: Making Affordable Medicines Available to All.

Check out the full press release, here: Link.